ANSI Advanced Neuromodulation Systems (MM)

ANS Introduces Industry's First Curved Leads Designed to Focus Stimulation for Pain Relief New Leads Facilitate Precise Lead Placement and More Efficient Use of ANS' Neurostimulation Systems PLANO, Texas, Sept. 1 /PRNewswire-FirstCall/ -- Advanced Neuromodulation Systems, Inc. (NASDAQ:ANSI) (ANS) today introduced its line of C-Series Lamitrode(R) leads, the market's first set of leads to mimic the curve of the epidural space -- the space between the spine and the spinal cord. These curved leads are designed to direct stimulation toward the spinal cord and to minimize unwanted stimulation in the posterior epidural space. Moreover, the C-Series Lamitrode leads facilitate lead insertion and placement. (Photo: http://www.newscom.com/cgi-bin/prnh/20040901/DAW008 ) "There is an observable and dramatic positive difference when placing ANS' C-Series leads during spinal cord stimulation cases," said Dr. F. Richard Jordan. "The curved design makes placement easier, decreases the chance for lead movement and helps to reduce overall operation time." The C-Series leads feature two rows of electrodes with wide lateral spacing to enhance bilateral stimulation. The electrodes are shielded to focus the electrical current in one direction. This unidirectional current makes it possible to provide therapy at lower power levels, resulting in greater system efficiency and longer battery life. "ANS' engineering team designed the C-Series Lamitrode leads to benefit the physician and patient," said ANS President and CEO Chris Chavez. "With this new product, we continue to demonstrate technology leadership in the rapidly growing neuromodulation market." The C-Series Lamitrode leads extend ANS' already broad line of neurostimulation leads. The breadth of this line allows physicians to select the lead that best fits each patient's unique anatomical needs. With the choices of percutaneous, surgical, and trial leads, physicians can facilitate precise stimulation and satisfy placement preferences without compromising performance. About chronic pain Chronic pain affects an estimated 50 million Americans, of whom more than half are partially or totally disabled. At present, approximately $100 billion are spent in the U.S. on the diagnosis and treatment of chronic pain, which represents the most common indication for spinal cord stimulation therapy. The 106th U.S. Congress has declared this the "Decade of Pain Control and Research," helping to bring spinal cord stimulation to the forefront as a viable and effective option in the treatment of chronic pain. About Advanced Neuromodulation Systems (ANS) Advanced Neuromodulation Systems, Inc. designs, develops, manufactures and markets implantable systems used to manage chronic intractable pain and other disorders of the central nervous system. A technology leader in the neuromodulation industry, ANS offers a family of proprietary neurostimulation devices and implantable drug pumps for an expanding range of therapeutic applications. ANS was recently named among FORTUNE's 100 Fastest Growing Companies and has been recognized among Forbes' 200 Best Small Companies for two consecutive years. Frost & Sullivan also honored the company with its Product Innovation Award. ANS is financially sound and growing, reporting 2003 net revenue of $91.1 million, up 37 percent from 2002. Additional information is available at http://www.ans-medical.com/ . http://www.newscom.com/cgi-bin/prnh/20040901/DAW008 DATASOURCE: Advanced Neuromodulation Systems, Inc. CONTACT: Megan Lozito, +1-972-716-0500, ext. 14, or , for Advanced Neuromodulation Systems, Inc. Web site: http://www.ans-medical.com/

Copyright